carmustine has been researched along with Mycosis Fungoides in 29 studies
Carmustine: A cell-cycle phase nonspecific alkylating antineoplastic agent. It is used in the treatment of brain tumors and various other malignant neoplasms. (From Martindale, The Extra Pharmacopoeia, 30th ed, p462) This substance may reasonably be anticipated to be a carcinogen according to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985). (From Merck Index, 11th ed)
carmustine : A member of the class of N-nitrosoureas that is 1,3-bis(2-chloroethyl)urea in which one of the nitrogens is substituted by a nitroso group.
Mycosis Fungoides: A chronic, malignant T-cell lymphoma of the skin. In the late stages, the LYMPH NODES and viscera are affected.
| Excerpt | Relevance | Reference |
|---|---|---|
| "In a phase 1 trial, single-dose O6-benzylguanine with topical carmustine for patients with early stage (stage IA through stage IIA) cutaneous T-cell lymphoma, mycosis fungoides (MF) type, resulted in clinical responses proportional to inhibition of O6-alkylguanine-DNA alkyltransferase activity, but a maximum tolerated dose (MTD) was not reached." | 9.24 | Evaluation of O6-Benzylguanine-Potentiated Topical Carmustine for Mycosis Fungoides: A Phase 1-2 Clinical Trial. ( Carlson, S; Chan, DV; Cooper, KD; Dowlati, A; Fu, P; Gerson, SL; Groft, S; Honda, K; Lu, K; McCormick, TS; Rosenjack, J; Tacastacas, JD, 2017) |
| "A total of 21 adult patients (11 male, 10 female)with early-stage (IA-IIA) refractory CTCL, mycosis fungoides type, treated with topical carmustine following intravenous O6-benzylguanine." | 9.16 | Phase I clinical trial of O6-benzylguanine and topical carmustine in the treatment of cutaneous T-cell lymphoma, mycosis fungoides type. ( Apisarnthanarax, N; Carlson, S; Chan, DV; Cooper, KD; Fu, P; Gerson, SL; Gilliam, AC; Liu, L; Remick, SC; Stevens, SR; Szabo, SK; Wood, GS, 2012) |
| "The University of California, San Francisco (UCSF), experience with topical carmustine (BCNU) in the treatment of approximately 200 patients with mycosis fungoides (MF) is summarized." | 8.82 | Topical carmustine (BCNU) in the treatment of mycosis fungoides. ( Zackheim, HS, 2003) |
| "This article summarizes experience with topical carmustine (BCNU) solution in 172 patients with patch/plaque stage mycosis fungoides." | 7.69 | Topical carmustine (BCNU) for patch/plaque mycosis fungoides. ( Zackheim, HS, 1994) |
| "A 10-year experience in eighty-six patients confirms the effectiveness of topical carmustine (BCNU) in mycosis fungoides (MF)." | 7.66 | Topical carmustine (BCNU) for mycosis fungoides and related disorders: a 10-year experience. ( Crain, WR; Epstein, EH; Grekin, DA; McNutt, NS; Zackheim, HS, 1983) |
| "The total percutaneous absorption of 1,3-bis(2-chloroethyl)-I-nitrosourea (BCNU, carmustine) in 5 patients with mycosis fungoides, based on the 5 day urinary excretion of 14C-labelled BCNU, ranged from 5 to 28%." | 7.65 | Percutaneous absorption of 1,3-bis (2-chloroethyl)-I-nitrosourea (BCNU, carmustine) in mycosis fungoides. ( Feldmann, RJ; Lindsay, C; Maibach, HI; Zackheim, HS, 1977) |
| "In a phase 1 trial, single-dose O6-benzylguanine with topical carmustine for patients with early stage (stage IA through stage IIA) cutaneous T-cell lymphoma, mycosis fungoides (MF) type, resulted in clinical responses proportional to inhibition of O6-alkylguanine-DNA alkyltransferase activity, but a maximum tolerated dose (MTD) was not reached." | 5.24 | Evaluation of O6-Benzylguanine-Potentiated Topical Carmustine for Mycosis Fungoides: A Phase 1-2 Clinical Trial. ( Carlson, S; Chan, DV; Cooper, KD; Dowlati, A; Fu, P; Gerson, SL; Groft, S; Honda, K; Lu, K; McCormick, TS; Rosenjack, J; Tacastacas, JD, 2017) |
| "A total of 21 adult patients (11 male, 10 female)with early-stage (IA-IIA) refractory CTCL, mycosis fungoides type, treated with topical carmustine following intravenous O6-benzylguanine." | 5.16 | Phase I clinical trial of O6-benzylguanine and topical carmustine in the treatment of cutaneous T-cell lymphoma, mycosis fungoides type. ( Apisarnthanarax, N; Carlson, S; Chan, DV; Cooper, KD; Fu, P; Gerson, SL; Gilliam, AC; Liu, L; Remick, SC; Stevens, SR; Szabo, SK; Wood, GS, 2012) |
| "The University of California, San Francisco (UCSF), experience with topical carmustine (BCNU) in the treatment of approximately 200 patients with mycosis fungoides (MF) is summarized." | 4.82 | Topical carmustine (BCNU) in the treatment of mycosis fungoides. ( Zackheim, HS, 2003) |
| "This article summarizes experience with topical carmustine (BCNU) solution in 172 patients with patch/plaque stage mycosis fungoides." | 3.69 | Topical carmustine (BCNU) for patch/plaque mycosis fungoides. ( Zackheim, HS, 1994) |
| "A 10-year experience in eighty-six patients confirms the effectiveness of topical carmustine (BCNU) in mycosis fungoides (MF)." | 3.66 | Topical carmustine (BCNU) for mycosis fungoides and related disorders: a 10-year experience. ( Crain, WR; Epstein, EH; Grekin, DA; McNutt, NS; Zackheim, HS, 1983) |
| "The total percutaneous absorption of 1,3-bis(2-chloroethyl)-I-nitrosourea (BCNU, carmustine) in 5 patients with mycosis fungoides, based on the 5 day urinary excretion of 14C-labelled BCNU, ranged from 5 to 28%." | 3.65 | Percutaneous absorption of 1,3-bis (2-chloroethyl)-I-nitrosourea (BCNU, carmustine) in mycosis fungoides. ( Feldmann, RJ; Lindsay, C; Maibach, HI; Zackheim, HS, 1977) |
| "Twenty-six patients with mycosis fungoides were treated topically with three nitrosourea compounds: carmustine (BCNU), lomustine (CCNU), and 1-methyl-1-nitrosourea." | 3.65 | Treatment of mycosis fungoides with topical nitrosourea compounds: Further studies. ( Epstein, EH; Zackheim, HS, 1975) |
| "Mycosis fungoides is a T-cell lymphoma which is often localized to the skin in the early stages." | 1.26 | Topical chemotherapy of mycosis fungoides. ( Epstein, EH; Grekin, DA; Zackheim, HS, 1979) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 12 (41.38) | 18.7374 |
| 1990's | 5 (17.24) | 18.2507 |
| 2000's | 6 (20.69) | 29.6817 |
| 2010's | 6 (20.69) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| de Quintana-Sancho, A | 1 |
| Acebo-Mariñas, E | 1 |
| Gardeazabal-García, J | 1 |
| Aperribay-Esparza, A | 1 |
| MacArthur, KM | 1 |
| Jariwala, N | 1 |
| Kim, EJ | 1 |
| Rook, AH | 1 |
| Tacastacas, JD | 1 |
| Chan, DV | 2 |
| Carlson, S | 2 |
| Gerson, SL | 2 |
| Dowlati, A | 1 |
| Fu, P | 2 |
| Lu, K | 1 |
| Groft, S | 1 |
| Rosenjack, J | 1 |
| Honda, K | 1 |
| McCormick, TS | 1 |
| Cooper, KD | 2 |
| Yazganoglu, KD | 1 |
| Topkarci, Z | 1 |
| Buyukbabani, N | 1 |
| Baykal, C | 1 |
| Fenot, M | 1 |
| Maillard, H | 1 |
| Sierra-Fortuny, S | 1 |
| De Ybarlucea, LR | 1 |
| Célérier, P | 1 |
| Apisarnthanarax, N | 1 |
| Wood, GS | 1 |
| Stevens, SR | 1 |
| Liu, L | 1 |
| Szabo, SK | 1 |
| Gilliam, AC | 1 |
| Remick, SC | 1 |
| Zackheim, HS | 12 |
| Dummer, R | 1 |
| Foss, F | 1 |
| Dreno, B | 1 |
| Bagot, M | 1 |
| Hsiao, PF | 1 |
| Hsiao, CH | 1 |
| Tsai, TF | 1 |
| Jee, SH | 1 |
| Pitman, J | 1 |
| Muekusch, G | 1 |
| Epstein, EH | 6 |
| McNutt, NS | 2 |
| Grekin, DA | 4 |
| Crain, WR | 2 |
| Herrmann, JJ | 1 |
| Roenigk, HH | 1 |
| Hurria, A | 1 |
| Kuzel, TM | 1 |
| Samuelson, E | 1 |
| Rademaker, AW | 1 |
| Rosen, ST | 1 |
| Richard-Lallemand, MA | 1 |
| Carsuzaa, F | 1 |
| Verret, JL | 1 |
| Rousselet, MC | 1 |
| Peria, P | 1 |
| Heald, PW | 1 |
| Glusac, EJ | 1 |
| Volk, AL | 1 |
| Vannucci, SA | 1 |
| Cook, W | 1 |
| Thompson, KA | 1 |
| Listinsky, CM | 1 |
| Epstein, JH | 1 |
| Feldmann, RJ | 1 |
| Lindsay, C | 1 |
| Maibach, HI | 1 |
| Bigler, RD | 1 |
| Crilley, P | 1 |
| Micaily, B | 1 |
| Brady, LW | 1 |
| Topolsky, D | 1 |
| Bulova, S | 1 |
| Vonderheid, EC | 1 |
| Brodsky, I | 1 |
| Marino, C | 1 |
| Smith, C | 1 |
| O'Quinn, JL | 1 |
| Kardashian, JL | 1 |
| Egbert, BM | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase I/II Multicenter Clinical Trial of O6Benzylguanine and Topical Carmustine in the Treatment of Refractory Early-Stage (IA-IIA) Cutaneous T-Cell Lymphoma[NCT00961220] | Phase 1/Phase 2 | 17 participants (Actual) | Interventional | 2010-02-01 | Completed | ||
| Phase I Trial of O6 Benzylguanine and BCNU in Cutaneous T-cell Lymphoma[NCT00003613] | Phase 1 | 20 participants (Anticipated) | Interventional | 1999-04-30 | Terminated | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
"Based on changes in modified SWAT assessment, patient responses will be classified as complete clinical response (CCR), partial response (PR), stable disease (SD), or progressive disease (PD). SWAT provides an accurate and reproducible assessment of cutaneous disease involvement based on body surface area of involvement and lesional thickness.~CCR: No evidence of disease, 100% improvement for a duration of at least 4 weeks. PR: Greater than or equal to 50% decrease in SWAT score compared to baseline and improvement is maintained for at least 4 weeks. SD: Less than 50% decrease in SWAT score compared to baseline. PD: Increase of greater or equal to 25% of the SWAT score compared to baseline while the patient is actively taking the study drug" (NCT00961220)
Timeframe: Up to 2 weeks after completion of study treatment
| Intervention | participants (Number) | |||
|---|---|---|---|---|
| Complete Clinical Response-confirmed | Complete Clinical Response-unconfirmed | Partial Response | Progressive Disease | |
| Treatment (O6-benzylguanine, Carmustine) | 6 | 2 | 8 | 1 |
2 reviews available for carmustine and Mycosis Fungoides
| Article | Year |
|---|---|
Topical carmustine (BCNU) in the treatment of mycosis fungoides.
Topics: Administration, Topical; Carmustine; Clinical Trials as Topic; Disease-Free Survival; Dose-Response | 2003 |
[Mycosis fungoides].
Topics: Antineoplastic Agents; Carmustine; Drug Therapy, Combination; Humans; Mechlorethamine; Mycosis Fungo | 1997 |
2 trials available for carmustine and Mycosis Fungoides
| Article | Year |
|---|---|
Evaluation of O6-Benzylguanine-Potentiated Topical Carmustine for Mycosis Fungoides: A Phase 1-2 Clinical Trial.
Topics: Administration, Cutaneous; Administration, Intravenous; Adult; Aged; Antineoplastic Combined Chemoth | 2017 |
Phase I clinical trial of O6-benzylguanine and topical carmustine in the treatment of cutaneous T-cell lymphoma, mycosis fungoides type.
Topics: Administration, Topical; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Biomarke | 2012 |
25 other studies available for carmustine and Mycosis Fungoides
| Article | Year |
|---|---|
Cerebral involvement as the first extracutaneous manifestation of mycosis fungoides.
Topics: Adrenal Cortex Hormones; Antineoplastic Combined Chemotherapy Protocols; Bexarotene; Brain; Carmusti | 2015 |
Topical Carmustine as Monotherapy or as Multimodality Therapy for Folliculotropic Mycosis Fungoides.
Topics: Administration, Cutaneous; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Antine | 2017 |
Childhood mycosis fungoides: a report of 20 cases from Turkey.
Topics: Adolescent; Adrenal Cortex Hormones; Bexarotene; Carmustine; Child; Child, Preschool; Humans; Mycosi | 2013 |
[Syringotropic cutaneous T-cell lymphoma mimicking dermatomycosis].
Topics: Carmustine; Clobetasol; Dermatomycoses; Diagnostic Errors; Female; Foot Diseases; Humans; Middle Age | 2012 |
Clinical experience: practical management of five patients with cutaneous T-cell lymphoma (CTCL)-related symptoms.
Topics: Aged; Antineoplastic Agents; Carmustine; Combined Modality Therapy; Dermatitis, Exfoliative; Erythem | 2006 |
Minimal residual disease in hypopigmented mycosis fungoides.
Topics: Adolescent; Antineoplastic Agents, Alkylating; Carmustine; Humans; Male; Mycosis Fungoides; Neoplasm | 2006 |
Mycosis fungoides.
Topics: Anti-Inflammatory Agents; Antineoplastic Agents, Alkylating; Carmustine; Causality; Humans; Mechlore | 2007 |
Topical carmustine (BCNU) for mycosis fungoides and related disorders: a 10-year experience.
Topics: Administration, Topical; Adult; Aged; Carmustine; Drug Administration Schedule; Female; Humans; Male | 1983 |
Prolonged topical maintenance therapy for mycosis fungoides.
Topics: Animals; Carmustine; Humans; Mechlorethamine; Mice; Mycosis Fungoides; Skin Neoplasms | 1983 |
Mycosis fungoides presenting as areas of hypopigmentation: a report of three cases.
Topics: Adult; Aged; Carmustine; Female; Humans; Male; Mycosis Fungoides; Pigmentation Disorders; Skin Neopl | 1982 |
Treatment of mycosis fungoides with photochemotherapy (PUVA): long-term follow-up.
Topics: Biopsy; Carmustine; Cohort Studies; Female; Follow-Up Studies; Humans; Male; Mechlorethamine; Middle | 1995 |
Topical carmustine (BCNU) for patch/plaque mycosis fungoides.
Topics: Administration, Topical; Adolescent; Adult; Aged; Aged, 80 and over; Carmustine; Female; Humans; Mal | 1994 |
[Unilesional plaque-type mycosis fungoides: 3 cases].
Topics: Aged; Antineoplastic Agents, Alkylating; Carmustine; Diagnosis, Differential; Female; Follow-Up Stud | 1997 |
Unilesional cutaneous T-cell lymphoma: clinical features, therapy, and follow-up of 10 patients with a treatment-responsive mycosis fungoides variant.
Topics: Administration, Topical; Adult; Aged; Antineoplastic Agents, Alkylating; Carmustine; Female; Humans; | 2000 |
Composite mycosis fungoides and B-cell chronic lymphocytic leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carmustine; Chlorambucil; Combined Modality Therapy; | 2002 |
Treatment of mycosis fungoides with topical BCNU.
Topics: Administration, Topical; Bone Marrow; Carmustine; Drug Eruptions; Humans; Mycosis Fungoides; Remissi | 1979 |
Topical chemotherapy of mycosis fungoides.
Topics: Administration, Topical; Carmustine; Humans; Mechlorethamine; Mycosis Fungoides; Skin Neoplasms | 1979 |
Stimulation of ultraviolet-induced carcinogenesis by 1,3-Bis(2-chloroethyl)-1-nitrosourea.
Topics: Administration, Topical; Animals; Carcinoma, Squamous Cell; Carmustine; Female; Mice; Mice, Nude; My | 1979 |
Percutaneous absorption of 1,3-bis (2-chloroethyl)-I-nitrosourea (BCNU, carmustine) in mycosis fungoides.
Topics: Aged; Carmustine; Female; Humans; Male; Middle Aged; Mycosis Fungoides; Skin Absorption; Skin Neopla | 1977 |
Treatment of mycosis fungoides with topical nitrosourea compounds: Further studies.
Topics: Administration, Topical; Adult; Aged; Bone Marrow; Carmustine; Cross Reactions; Drug Hypersensitivit | 1975 |
Autologous bone marrow transplantation for advanced stage mycosis fungoides.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Cisp | 1991 |
Mycosis fungoides treated with high-dose carmustine.
Topics: Aged; Carmustine; Female; Humans; Medication Errors; Mycosis Fungoides; Skin Neoplasms | 1987 |
Lymphomatoid papulosis associated with plaque-stage and granulomatous mycosis fungoides.
Topics: Administration, Topical; Carmustine; Granuloma; Humans; Male; Middle Aged; Mycosis Fungoides; Skin D | 1985 |
Topical carmustine therapy for lymphomatoid papulosis.
Topics: Administration, Topical; Carmustine; Female; Humans; Male; Middle Aged; Mycosis Fungoides; Skin Dise | 1985 |
Treatment of mycosis fungoides with topical nitrosourea compounds.
Topics: Aged; Blood Cell Count; Carmustine; Female; Humans; Male; Middle Aged; Mycosis Fungoides; Nitroso Co | 1972 |